Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: A tissue microarray and automated quantitative analysis

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 1, 2009, Pages 23-30

  Warren, Miranda ^a   Twohig, Matthew ^a   Pier, Thomas ^a   Eickhoff, Jens ^a   Lin, Chen Yong ^c,d   Jarrard, David ^b   Huang, Wei ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AQUA; Hepatocyte growth factor activator inhibitor 1; Matriptase; Prostate cancer

Indexed keywords

HEPATOCYTE GROWTH FACTOR INHIBITOR 1; INHIBITOR PROTEIN; MATRIPTASE; TUMOR MARKER; UNCLASSIFIED DRUG; LEUKOCYTE ELASTASE INHIBITOR; SERINE PROTEINASE; SPINT1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TISSUE TYPES; VALIDATION STUDY; AUTOMATION; COMPUTER ASSISTED DIAGNOSIS; DISEASE COURSE; EPITHELIUM CELL; INSTRUMENTATION; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

AUTOMATION; CELL PROLIFERATION; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE PROGRESSION; EPITHELIAL CELLS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS;

EID: 58749104425     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31817c3334     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Guichard G, Larre S, Gallina A, et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol. 2007;52:430-435. (Pubitemid 46963444)
3. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J Urol. 2007;25:11-17.
4. Klotz LH. International regional working groups on prostate cancer: results of consensus development. Can J Urol. 2005;12(suppl 1): 86-91.
5. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51:1244-1250; discussion 1251.
6. Sanchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003;54:238-247. (Pubitemid 36120322)
7. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439-443.
8. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007; 99:526-532. (Pubitemid 47073555)
9. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem. 2001;268:1439-1447. (Pubitemid 32231898)
10. Suzuki H, Akakura K, Igarashi T, et al. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol. 2004; 171:182-186. (Pubitemid 37549119)
11. Johnson MD, Oberst MD, Lin CY, et al. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2003; 3:331-338. (Pubitemid 36612204)
12. Lee JW, Yong Song S, Choi JJ, et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol. 2005;36:626-633. (Pubitemid 40922568)
13. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med. 2006;12:1-7. (Pubitemid 44128372)
14. Saleem M, Adhami VM, Zhong W, et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 2006;15:217-227. (Pubitemid 43342167)
15. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003;63:1101-1105. (Pubitemid 36278444)
16. Oberst MD, Johnson MD, Dickson RB, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res. 2002;8:1101-1107.
17. Jin JS, Cheng TF, Tsai WC, et al. Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol Histopathol. 2007;22:305-309.
18. Cheng MF, Tzao C, Tsai WC, et al. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus. 2006;19:482-486. (Pubitemid 44644686)
19. Jin X, Yagi M, Akiyama N, et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 2006;97:1327-1334. (Pubitemid 44614984)
20. Shimomura T, Denda K, Kitamura A, et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem. 1997;272:6370-6376. (Pubitemid 27118113)
21. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol. 2001;158:1301-1311. (Pubitemid 32281294)
22. Oberst MD, Chen LY, Kiyomiya K, et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol. 2005;289:C462-C470. (Pubitemid 41008893)
23. Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 2006;119:1176-1183. (Pubitemid 44116927)
24. Benaud CM, Oberst M, Dickson RB, et al. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis. 2002; 19:639-649. (Pubitemid 35454575)
25. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327. (Pubitemid 35373567)
26. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alphamethylacyl- CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol. 2004;164:831-840.
27. Bamias A, Yu Z, Weinberger PM, et al. Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer. Ann Oncol. 2006;17: 1797-1802. (Pubitemid 44884055)
28. Psyrri A, Kountourakis P, Yu Z, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol. 2007;18:709-715. (Pubitemid 46523275)
29. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007; 87:662-669.
30. Dolled-Filhart M, McCabe A, Giltnane J, et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006; 66:5487-5494.
31. Psyrri A, Yu Z, Weinberger PM. et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11:5856-5862.
32. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-methylacyl coenzyme a racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-1670.
33. Zheng SL, Chang BL, Faith DA, et al. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostrate cancer risk. Cancer Res. 2002;62:6485-6488.
34. Herawi M, Parwani AV, Irie J, et al. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29:874-880.
35. Lin CY, Wang JK, Torri J, et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem. 1997;272:9147-9152.
36. Lin CY, Anders J, Johnson M, et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem. 1999;274: 18237-18242.
37. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62: 2220-2226.
38. Tanimoto H, Shigemasa K, Tian X, et al. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br J Cancer. 2005;92:278-283.
39. Kiyomiya K, Lee MS, Tseng IC, et al. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol. 2006;291:C40-C49.
40. Liotta LA, Clair T. Cancer. Checkpoint for invasion. Nature. 2000;405:287-288.
41. Nicolson GL. Tumor and host molecules important in the organ preference of metastasis. Semin Cancer Biol. 1991;2:143-154.
42. Polette M, Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol. 1998;30:1195-1202.
43. Iida J, Wilhelmson KL, Price MA, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol. 2004;122:167-176.
44. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci. 2006;63:2968-2978.
45. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205-222.
46. Qiu D, Owen K, Gray K, et al. Roles and regulation of membrane-associated serine proteases. Biochem Soc Trans. 2007;35(Pt 3): 583-587.
47. Kilpatrick LM, Harris RL, Owen KA, et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood. 2006;108: 2616-2623.
48. Johansson N, Kahari VM. Matrix metalloproteinases in squamous cell carcinoma. Histol Histopathol. 2000;15:225-237.
49. Nagaike K, Kohama K, Uchiyama S, et al. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci. 2004; 95:728-735.
50. Itoh H, Kataoka H, Tomita M, et al. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol Gastrointest Liver Physiol. 2000; 278:G635-G643.
51. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97: 1808-1815.